Angion Biomedica Stock News

Angion Biomedica Corp. (NASDAQ:ANGN) insider Itzhak Goldberg sold 40,215 shares of the companys stock in a transaction that occurred on Friday, December 3rd. The shares were sold at an average price of $3.39, for a total value of $136,328.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Angion Biomedica Corp. (NASDAQ:ANGN) Equities researchers at Oppenheimer raised their FY2021 earnings per share (EPS) estimates for Angion Biomedica in a report released on Monday, November 15th. Oppenheimer analyst J. Kim now forecasts that the company will post earnings of ($3.20) per share for the year, up from their prior forecast of ($3.52). Oppenheimer []

Angion Biomedica (NASDAQ:ANGN)s stock had its buy rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Monday, Analyst Price Targets reports. They currently have a $49.00 price target on the stock. Several other brokerages have also recently issued reports on ANGN. Stifel Nicolaus decreased their price target on shares of []

A number of firms have modified their ratings and price targets on shares of Angion Biomedica (NASDAQ: ANGN) recently: 11/15/2021 Angion Biomedica had its buy rating reaffirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock. 11/11/2021 Angion Biomedica was upgraded by analysts at Zacks Investment Research []

HC Wainwright reissued their buy rating on shares of Angion Biomedica (NASDAQ:ANGN) in a report issued on Monday, Price Targets.com reports. They currently have a $49.00 price objective on the stock. ANGN has been the subject of several other research reports. Stifel Nicolaus reduced their price objective on shares of Angion Biomedica from $40.00 to []

UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel s

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sm

Angion Biomedica Corp (NASDAQ: ANGN) has announced positive results from its Phase 1 study in healthy volunteers for ANG-3070 for fibrotic diseases.  In the 97-volunteer trial, ANG-3070 achieved d

UNIONDALE, N.Y., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma

UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sm

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion's AKI-002-15 stud

Topline data expected in the second half of 2021 Topline data expected in the second half of 2021

Angion is a recent IPO. It has an ongoing phase 3 trial with near-term data readout.

UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel s